We are live on ! Find out more

Propanc Biopharma

PPCB

Market cap $18.1M

1.84 USD

-0.27

12.8%

At close Updated Oct 30, 4:00 PM EDT

Pre-market

After hours

1.90

+0.06

3.26%

1 day

-12.8%

5 days

-38.67%

1 month

-62.75%

3 months

-82.31%

6 months

-92.76%

Year to date

-98.71%

1 year

-99.41%

5 years

-99.74%

10 years

-99.74%

About: Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.

Employees: 2

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 5.6%

Neutral 94.4%

Negative 0%

Propanc Biopharma Advances Bioanalytical & Immunogenicity Assay Development for Phase 1b First-In-Human Study in up to 50 Advanced Cancer Patients

MELBOURNE, Australia, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases including recurrent and metastatic cancer, today announced that key analytical development activities are underway, including immunogenicity assay feasibility, pharmacokinetic method optimization and stability testing, supporting preparations for the planned Phase 1b, First-In-Human study of the Company's lead clinical candidate, PPC-001, in up to 50 advanced cancer patients with solid tumors. “Propanc continues to advance its analytical development activities in parallel with preparations for its Phase 1b First-In-Human study,” said Dr. Ralf Brandt, Propanc's Research & Development Director.

Propanc Biopharma Advances Bioanalytical & Immunogenicity Assay Development for Phase 1b First-In-Human Study in up to 50 Advanced Cancer Patients

Propanc Biopharma Advances Clinical Development Preparation for PRP Phase 1b First-In-Human Study in Up to 50 Advanced Cancer Patients

"The continued advancement

Propanc Biopharma Advances Clinical Development Preparation for PRP Phase 1b First-In-Human Study in Up to 50 Advanced Cancer Patients

Propanc Biopharma Publishes New Data: PRP Reprograms Chemotherapy-Resistant Pancreatic Cancer Cells & Restores Therapeutic Vulnerability

We envision PRP as a long-term, metronomic therapy that minimizes the threat of recurrence while enabling patients to better respond to standard treatments

Propanc Biopharma Publishes New Data: PRP Reprograms Chemotherapy-Resistant Pancreatic Cancer Cells & Restores Therapeutic Vulnerability

CORRECTION -- Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans

CORRECTION -- Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans

Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans

MELBOURNE, Australia, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases including recurrent and metastatic cancer, today announced that its Board of Directors, approved a 1-for-10 reverse stock split of the Company's issued and outstanding shares of common stock, par value $0.001 per share (“Reverse Stock Split”). The Reverse Stock Split is anticipated to be effective as of the open of the market October 26, 2026.

Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans

Propanc Biopharma's Lead Asset PRP Reprograms Chemotherapy-Resistant Pancreatic Cancer Cells

MELBOURNE, Australia, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases including recurrent and metastatic cancer, today announced new preclinical research from an academic–industry collaboration from the Universities of Jaén and Granada, led by Dr. Maria Belén Toledo, has identified pancreatic proenzyme formulation, PRP, as a potential strategy for addressing chemotherapy resistance in pancreatic cancer. Chemotherapy-resistant tumor cells can acquire adaptive cellular states that allow them to survive treatment and maintain aggressive characteristics.

Propanc Biopharma's Lead Asset PRP Reprograms Chemotherapy-Resistant Pancreatic Cancer Cells

Propanc Biopharma Announces Publication of Pilot Study Demonstrating Potent Anti-Tumor Efficacy of PRP Pancreatic Proenzyme Formulation in Pancreatic & Ovarian Cancer

MELBOURNE, Australia, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases including recurrent and metastatic cancer, today announced the publication of a peer-reviewed pilot study in Scientific Reports (Nature Publishing Group) titled “A formulation of pancreatic pro-enzymes provides potent anti-tumor efficacy: a pilot study focused on pancreatic and ovarian cancer.” The study evaluates PRP, the Company's proprietary fixed-ratio combination of the pancreatic proenzymes Trypsinogen and Chymotrypsinogen A (1:6).

Propanc Biopharma Announces Publication of Pilot Study Demonstrating Potent Anti-Tumor Efficacy of PRP Pancreatic Proenzyme Formulation in Pancreatic & Ovarian Cancer

Propanc Biopharma Reports Data Showing 90% Tumor Growth Inhibition with PRP in Pancreatic Cancer Models, Contrasting Profile with Revolution Medicines' Daraxonrasib

MELBOURNE, Australia, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases including recurrent and metastatic cancer, today highlighted new preclinical data for its lead candidate PRP in pancreatic ductal adenocarcinoma (PDAC) and compared that profile with a clinical standard recently established by Revolution Medicines, Inc. On August 26, 2026, the U.S. Food and Drug Administration approved daraxonrasib (RASONQUE), Revolution Medicines' oral RAS(ON) multi-selective inhibitor, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy, or who are not candidates for multiagent systemic therapy. Approval was based on the Phase 3 RASolute 302 trial.

Propanc Biopharma Provides Corporate Update & Year-End June 30, 2025-26, Financial Results

"The Company is poised to capitalize on the foundation set

Propanc Biopharma Provides Corporate Update & Year-End June 30, 2025-26, Financial Results

Propanc Biopharma Highlights Differentiated PRP Pancreatic Cancer Data Versus Emerging Pan-RAS Program ERAS-0015

New Preclinical PDAC Package for PRP Shows >90% Tumor-Growth Inhibition & >2.5-Fold Survival Benefit; Company Contrasts Mechanism, Breadth, & Development Role Against Erasca's Phase 1 ERAS-0015 Dataset MELBOURNE, Australia, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today issued a comparative analysis of lead candidate PRP against recently reported clinical datasets from Erasca, Inc.'s pan-RAS molecular glue ERAS-0015 in pancreatic ductal adenocarcinoma (PDAC).

Propanc Biopharma Highlights Differentiated PRP Pancreatic Cancer Data Versus Emerging Pan-RAS Program ERAS-0015

See News Rankings

Price charts implemented using Lightweight Charts™